Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 11/2010

01-11-2010 | Original Article

Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion

Authors: Alexander J. Muller, James B. DuHadaway, Mee Young Chang, Arivudinambi Ramalingam, Erika Sutanto-Ward, Janette Boulden, Alejandro P. Soler, Laura Mandik-Nayak, Susan K. Gilmour, George C. Prendergast

Published in: Cancer Immunology, Immunotherapy | Issue 11/2010

Login to get access

Abstract

Indoleamine 2,3-dioxygenase (IDO) is generally considered to be immunosuppressive but recent findings suggest this characterization oversimplifies its role in disease pathogenesis. Recently, we showed that IDO is essential for tumor outgrowth in the classical two-stage model of inflammatory skin carcinogenesis. Here, we report that IDO loss did not exacerbate classical inflammatory responses. Rather, IDO induction could be elicited by environmental signals and tumor promoters as an integral component of the inflammatory tissue microenvironment even in the absence of cancer. IDO loss had limited impact on tumor outgrowth in carcinogenesis models that lacked an explicit inflammatory tumor promoter. In the context of inflammatory carcinogenesis where IDO was critical to tumor development, the most important source of IDO was radiation-resistant non-hematopoietic cells, consistent with evidence that loss of the IDO regulatory tumor suppressor gene Bin1 in transformed skin cells facilitates IDO-mediated immune escape by a cell autonomous mechanism. Taken together, our results identify IDO as an integral component of ‘cancer-associated’ inflammation that tilts the immune system toward tumor support. More generally, they promote the concept that mediators of immune escape and cancer-associated inflammation may be genetically synonymous.
Appendix
Available only for authorised users
Literature
1.
go back to reference Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545CrossRefPubMed Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539–545CrossRefPubMed
2.
go back to reference Peek RM, Mohla S, DuBois RN (2005) Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a National Cancer Institute-sponsored meeting. Cancer Res 65:8583–8586CrossRefPubMed Peek RM, Mohla S, DuBois RN (2005) Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a National Cancer Institute-sponsored meeting. Cancer Res 65:8583–8586CrossRefPubMed
4.
go back to reference Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217CrossRefPubMed Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217CrossRefPubMed
5.
go back to reference Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148CrossRefPubMed Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148CrossRefPubMed
6.
go back to reference Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13(18 Pt 1):5256–5261CrossRefPubMed Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13(18 Pt 1):5256–5261CrossRefPubMed
7.
go back to reference Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev 213:146–158CrossRefPubMed Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev 213:146–158CrossRefPubMed
8.
go back to reference Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171):903–907CrossRefPubMed Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450(7171):903–907CrossRefPubMed
9.
go back to reference Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O’Carroll K et al (2001) Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98(4):1070–1077CrossRefPubMed Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O’Carroll K et al (2001) Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98(4):1070–1077CrossRefPubMed
10.
go back to reference Yu P, Rowley DA, Fu YX, Schreiber H (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18(2):226–231CrossRefPubMed Yu P, Rowley DA, Fu YX, Schreiber H (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18(2):226–231CrossRefPubMed
11.
go back to reference Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A et al (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204(1):49–55CrossRefPubMed Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A et al (2007) Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204(1):49–55CrossRefPubMed
12.
go back to reference Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J et al (2007) Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396(1):203–213CrossRefPubMed Ball HJ, Sanchez-Perez A, Weiser S, Austin CJ, Astelbauer F, Miu J et al (2007) Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396(1):203–213CrossRefPubMed
13.
go back to reference Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor IDO inhibitory compound D-1MT. Cancer Res 67:7082–7087CrossRefPubMed Metz R, DuHadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor IDO inhibitory compound D-1MT. Cancer Res 67:7082–7087CrossRefPubMed
14.
go back to reference Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147–1154CrossRefPubMed Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147–1154CrossRefPubMed
15.
go back to reference Mellor AL, Sivakumar J, Chandler PKS, Molina H, Mao D et al (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2:64–68CrossRefPubMed Mellor AL, Sivakumar J, Chandler PKS, Molina H, Mao D et al (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2:64–68CrossRefPubMed
16.
go back to reference Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193CrossRefPubMed Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B et al (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193CrossRefPubMed
17.
go back to reference Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312–319CrossRefPubMed Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312–319CrossRefPubMed
18.
go back to reference Muller AJ, Prendergast GC (2007) Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 7(1):31–40CrossRefPubMed Muller AJ, Prendergast GC (2007) Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 7(1):31–40CrossRefPubMed
19.
go back to reference Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA III et al (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 105(44):17073–17078CrossRefPubMed Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA III et al (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 105(44):17073–17078CrossRefPubMed
20.
go back to reference Chang M, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP et al (2007) Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 67:7605–7612CrossRefPubMed Chang M, Boulden J, Katz JB, Wang L, Meyer TJ, Soler AP et al (2007) Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 67:7605–7612CrossRefPubMed
21.
go back to reference Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K (1991) Resolution and characterization of pro-B and pre-B cell stages in normal mouse bone marrow. J Exp Med 173:1213–1225CrossRefPubMed Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K (1991) Resolution and characterization of pro-B and pre-B cell stages in normal mouse bone marrow. J Exp Med 173:1213–1225CrossRefPubMed
22.
go back to reference Chang M, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ et al (2007) Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 67:100–107CrossRefPubMed Chang M, Boulden J, Sutanto-Ward E, Duhadaway JB, Soler AP, Muller AJ et al (2007) Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 67:100–107CrossRefPubMed
23.
go back to reference Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M et al (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2):792–801CrossRefPubMed Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M et al (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2):792–801CrossRefPubMed
24.
go back to reference Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC (2010) Immunotherapeutic suppression of IDO and tumor growth by ethyl pyruvate. Cancer Res 70(5):1845–1853CrossRefPubMed Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC (2010) Immunotherapeutic suppression of IDO and tumor growth by ethyl pyruvate. Cancer Res 70(5):1845–1853CrossRefPubMed
25.
go back to reference Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27(1):68–73CrossRefPubMed Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA et al (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27(1):68–73CrossRefPubMed
26.
go back to reference Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330–336CrossRefPubMed Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4(4):330–336CrossRefPubMed
27.
go back to reference Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985–988CrossRefPubMed Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985–988CrossRefPubMed
28.
go back to reference Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541–547CrossRefPubMed Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541–547CrossRefPubMed
29.
go back to reference Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A et al (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171(4):1652–1655PubMed Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A et al (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171(4):1652–1655PubMed
30.
go back to reference Robinson CM, Shirey KA, Carlin JM (2003) Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 23(8):413–421CrossRefPubMed Robinson CM, Shirey KA, Carlin JM (2003) Synergistic transcriptional activation of indoleamine dioxygenase by IFN-gamma and tumor necrosis factor-alpha. J Interferon Cytokine Res 23(8):413–421CrossRefPubMed
31.
go back to reference Prendergast GC, Jaffee EM (2007) Cancer immunologists and cancer biologists: why we didn’t talk then but need to now. Cancer Res 67(8):3500–3504CrossRefPubMed Prendergast GC, Jaffee EM (2007) Cancer immunologists and cancer biologists: why we didn’t talk then but need to now. Cancer Res 67(8):3500–3504CrossRefPubMed
32.
go back to reference Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C et al (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12(4):1144–1151CrossRefPubMed Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C et al (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12(4):1144–1151CrossRefPubMed
33.
go back to reference Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R et al (2008) High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 93(12):1894–1898CrossRefPubMed Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R et al (2008) High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica 93(12):1894–1898CrossRefPubMed
34.
go back to reference Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K et al (2006) Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95(11):1555–1561CrossRefPubMed Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K et al (2006) Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 95(11):1555–1561CrossRefPubMed
35.
go back to reference Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y et al (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16):6030–6039CrossRefPubMed Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y et al (2005) Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16):6030–6039CrossRefPubMed
36.
go back to reference Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J et al (2008) Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(11):1247–1253CrossRefPubMed Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J et al (2008) Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 134(11):1247–1253CrossRefPubMed
37.
go back to reference Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N (2009). Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 26(8):1005–1012 Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N (2009). Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 26(8):1005–1012
38.
go back to reference Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214(1):8–14CrossRefPubMed Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214(1):8–14CrossRefPubMed
39.
go back to reference Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J et al (2009) Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84(4):304–309 Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J et al (2009) Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 84(4):304–309
40.
go back to reference Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, Flockhart D et al (2009) Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmactogenet Genomics 19:464–476CrossRef Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, Flockhart D et al (2009) Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmactogenet Genomics 19:464–476CrossRef
41.
go back to reference Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ et al (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 208(5):781–787 (discussion 7–9)CrossRefPubMed Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ et al (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 208(5):781–787 (discussion 7–9)CrossRefPubMed
42.
go back to reference Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6(8):613–625CrossRefPubMed Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6(8):613–625CrossRefPubMed
43.
go back to reference Griner EM, Kazanietz MG (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7(4):281–294CrossRefPubMed Griner EM, Kazanietz MG (2007) Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7(4):281–294CrossRefPubMed
44.
go back to reference Sayama S, Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O (1981) Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci USA 78(12):7327–7330CrossRefPubMed Sayama S, Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O (1981) Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci USA 78(12):7327–7330CrossRefPubMed
45.
go back to reference Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA et al (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177(4):2391–2402PubMed Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA et al (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177(4):2391–2402PubMed
46.
go back to reference Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH et al (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32(1):22–28CrossRefPubMed Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH et al (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32(1):22–28CrossRefPubMed
47.
go back to reference Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ et al (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280–290PubMed Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ et al (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280–290PubMed
Metadata
Title
Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion
Authors
Alexander J. Muller
James B. DuHadaway
Mee Young Chang
Arivudinambi Ramalingam
Erika Sutanto-Ward
Janette Boulden
Alejandro P. Soler
Laura Mandik-Nayak
Susan K. Gilmour
George C. Prendergast
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0891-4

Other articles of this Issue 11/2010

Cancer Immunology, Immunotherapy 11/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine